Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community
22 11월 2023 - 6:00AM
Business Wire
- Presenting new posters including favorable drug interaction,
pharmacokinetic and pharmacodynamic data further highlighting the
potential of LP352 to be a best-in-class therapy for a broad range
of Developmental and Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that it will present data for LP352, a novel, highly selective
investigational treatment in development for seizures associated
with a range of Developmental and Epileptic Encephalopathies
(DEEs), in poster sessions at the 2023 AES Annual Meeting.
Longboard will also host a scientific exhibit with members of its
leadership team to highlight details of the ongoing PACIFIC study,
and to discuss LP352 as a potential best-in-class therapy for
people living with rare seizure disorders.
“We believe that LP352 has the promise to be a best-in-class
therapy for a broad range of DEEs, and we remain committed to
moving the space forward. The AES annual meeting gives us the
opportunity to collaborate live with the top thought leaders, as we
approach PACIFIC topline data in January 2024 and plan for our
Phase 3 program for LP352. We look forward to presenting new
posters and hosting a scientific exhibit to highlight the
differentiating qualities of LP352 and our unique development plan.
I am also pleased to continue our work with key advocacy
organizations, including participation in the Rare Epilepsy
Network’s panel: Clustering Rare Epilepsies for Research, Trials
& Care,” stated Dr. Randall Kaye, Longboard’s Chief Medical
Officer.
Presentation & Event Details:
Title: Alternate Dosing Regimens for an Immediate Release
Formulation of the Novel Antiseizure Medication LP352 Based on
Pharmacokinetics (Plasma and CSF) and Pharmacodynamics (QEEG)
Poster number: 3.269 Date/Time: December 4, 2023,
from 12:00pm-1:45pm ET Location: West Hall C, Level 2
Title: LP352 has Negligible CYP or P-glycoprotein
Interaction Potential, Minimizing Therapeutic Complexity in
Epilepsy Patients With a High Burden of Polypharmacy Poster
number: 3.270 Date/Time: December 4, 2023, from
12:00pm-1:45pm ET Location: West Hall C, Level 2
Title: LP352, a 5-HT2C Superagonist, Has Broad
Antiepileptic Activity in Preclinical Seizure Models Poster
number: 3.261 Date/Time: December 4, 2023, from
12:00pm-1:45pm ET Location: West Hall C, Level 2
Longboard Scientific Exhibit: A Novel 5-HT2C Superagonist
for Treatment of Rare Seizure Disorders: LP352 and the PACIFIC
Study Date/Time: December 4, 2023, from 2:00pm-5:00pm ET
Location: Meeting Room #W315A, Orange County Convention
Center, West Concourse, Level 3
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of GPCR
research. Longboard is evaluating LP352, an oral, centrally acting
5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no
observed impact on 5-HT2B and 5-HT2A receptor subtypes. LP352 is
currently in a Phase 1b/2a clinical trial, the PACIFIC Study,
evaluating participants ages 12 to 65 years old with a broad range
of Developmental and Epileptic Encephalopathies (DEEs), including
Lennox-Gastaut syndrome, Dravet syndrome and other DEEs. Enrollment
was completed in the summer of 2023, and topline data are expected
in January 2024. Longboard is also evaluating LP659, an oral,
centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1
and 5 modulator, which is in development for the potential
treatment of rare neuroinflammatory conditions. Longboard expects
to initiate dosing in a Phase 1 single-ascending dose (SAD)
clinical trial for LP659 in healthy volunteers later this year.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. In
some cases, you can identify forward-looking statements by words
such as “commitment”, “potential”, “focus”, “will”, “believe”,
“promise”, “opportunity”, “January 2024”, “plan”, “look forward
to”, “working to”, “designed to”, “expect”, “later this year”, or
the negative, plural or other tenses of these words or other
comparable language, and they may include, without limitation,
statements about the following: Longboard’s participation at the
upcoming AES Annual Meeting; Longboard’s clinical and preclinical
product candidates and programs, including their advancement,
timing of initiating dosing in clinical trials, timing of topline
data from clinical trials, characteristics of clinical trial
participants, their potential (including to be highly selective and
the numbers and types of conditions they may address), and their
design and characteristics; Longboard’s ability to develop product
candidates and deliver medicines; and Longboard’s focus and work.
For such statements, Longboard claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Longboard’s expectations. Factors that
could cause actual results to differ materially from those stated
or implied by Longboard’s forward-looking statements include, but
are not limited to, the following: risks related to Longboard’s
limited operating history, financial position and need for
additional capital; Longboard will need additional managerial and
financial resources to advance all of its programs, and you and
others may not agree with the manner Longboard allocates its
resources; risks related to the development and commercialization
of Longboard’s product candidates; Longboard’s product candidates
are in the early phases of a lengthy research and development
process, the timing, manner and outcome of research, development
and regulatory review is uncertain, and Longboard’s product
candidates may not advance in research or development or be
approved for marketing; enrolling participants in Longboard’s
ongoing and intended clinical trials is competitive and
challenging; PACIFIC Study participants’ diagnoses are as of time
of screening and are subject to change; macroeconomic events
stemming from the COVID-19 pandemic or evolving geopolitical
developments such as the conflicts in Ukraine and the Middle East,
including but not limited to the impact on Longboard’s clinical
trials and operations, the operations of Longboard’s suppliers,
partners, collaborators, and licensees, and capital markets, which
in each case remains uncertain; risks related to unexpected or
unfavorable new data; nonclinical and clinical data is voluminous
and detailed, and regulatory agencies may interpret or weigh the
importance of data differently and reach different conclusions than
Longboard or others, request additional information, have
additional recommendations or change their guidance or requirements
before or after approval; results of clinical trials and other
studies are subject to different interpretations and may not be
predictive of future results; topline data may not accurately
reflect the complete results of a particular study or trial; risks
related to relying on licenses or collaborative arrangements; other
risks related to Longboard’s dependence on third parties;
competition; product liability or other litigation or disagreements
with others; government and third-party payor actions, including
relating to reimbursement and pricing; risks related to regulatory
compliance; and risks related to Longboard’s and third parties’
intellectual property rights. Additional factors that could cause
actual results to differ materially from those stated or implied by
Longboard’s forward-looking statements are disclosed in Longboard’s
filings with the Securities and Exchange Commission (SEC). These
forward-looking statements represent Longboard’s judgment as of the
time of this release. Longboard disclaims any intent or obligation
to update these forward-looking statements, other than as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231121857261/en/
Megan E. Knight Head of Investor Relations
IR@longboardpharma.com 619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024